Oct 9 (Reuters) - **Shares of drugmaker Viatris
up 1% at $11.44
** Co's drug Effexor meets primary and secondary goals in late-stage study for treatment of generalized anxiety disorder (GAD) in adult Japanese patients
** Study shows Effexor worked better than placebo in treating anxiety at 8 weeks
** Effexor was generally well-tolerated, consistent with known safety profile in non-Japanese patients
** Co targets submission of application for Effexor to Japan's regulator in 2025
** Effexor is approved to treat GAD in more than 80 countries
** Including session's move, stock up 5.2% YTD
(Reporting by Khusbu Jena)
((Khusbu.Jena@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.